© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
June 18, 2020
Dr. Caron A. Jacobson discusses the potential long-term impact of Yescarta for patients with relapsed or refractory indolent non-Hodgkin lymphoma and how it could turn an incurable disease into something curable.
FDA’s Approval of Keytruda-Based Regimen for Certain Stomach Cancer Subtypes ‘Really Exciting’ For Patients
Heart Failure May Increase Cancer Risk
Easing Worried Patients During Difficult Times Throughout Cancer Treatment
A Trail of Crumbs